Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11722748 | 0.81 | CHRNA4 (0.36) | CHRNA4RAB9AALDH1A1RAPGEF3RAPGEF4 | |
| SCHEMBL6050489 | 0.81 | MLYCD (0.37) | CHRNA4RAB9AALDH1A1RAPGEF3RAPGEF4 | |
| SCHEMBL28399251 | 0.79 | ALDH1A1 (0.50) | RAB9ASMN1; SMN2ALDH1A1HPGDKDM4A | |
| SCHEMBL27654528 | 0.77 | CHRNA4 (0.33) | CHRNA4 | |
| SCHEMBL353627 | 0.76 | S1PR4 (0.35) | CHRNA4RAB9ASMN1; SMN2RAPGEF3RAPGEF4 | |
| SCHEMBL28273457 | 0.75 | CHRNA4 (0.44) | CHRNA4RAB9ASMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9512940 | 0.75 | HSD17B1 (0.51) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL109365 | 0.73 | — | — | |
| SCHEMBL1323514 | 0.73 | — | — | |
| SCHEMBL17594489 | 0.72 | NPC1 (0.42) | CHRNA4RAB9AHPGDPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116582-B | mGluR2 antagonist | 大连大学 | 2022-07-29 | — | — | CN | claimed |
| CN-111116582-A | mGluR2 antagonist | 大连大学 | 2020-05-08 | — | — | CN | claimed |
| CN-111116582-B | mGluR2 antagonist | 大连大学 | 2022-07-29 | — | — | CN | disclosed |
| CN-111116582-A | mGluR2 antagonist | 大连大学 | 2020-05-08 | — | — | CN | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-20 | — | — | US | disclosed |
| WO-2016001789-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS FOR USE IN THE TREATMENT OF CANCER | PFIZER INC. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2015181063-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-03 | — | — | WO | disclosed |
| EP-2358709-A2 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | E. I. du Pont de Nemours and Company (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010130944-A1 | CYCLOPENTA[C]PYRROLE-2-CARBOXYLATE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010065579-A2 | FUNGICIDAL HETEROCYCLIC COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-6362212-B1 | POTENT FUNGICIDAL ACTIVITY | SHIONOGI & COMPANY, LTD. (JP) | 2002-03-26 | — | — | US | disclosed |
| US-20020032227-A1 | Oxime derivative and bactericide containing the same as active ingredient | TAKASE AKIRA (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6268312-B1 | FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6048885-A | FUNGICIDES | SHIONOGI & CO., LTD. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0754684-A1 | OXIME DERIVATIVE AND BACTERICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIONOGI & CO., LTD. (JP) | 1997-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032227-A1 | Oxime derivative and bactericide containing the same as active ingredient | MSMO1, O60361, CBR1 | CHRNA4 4148/4885RAB9A 3734/4885SMN1; SMN2 2104/4885 |
| US-20170107229-A1 | SUBSTITUTED TETRAHYDROPYRIDOTHIENOPYRIMIDINES | TYMP, DPYD, TYMS | CHRNA4 4879/4885RAB9A 3037/4885SMN1; SMN2 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.